India’s Bharat Enters Zika Fray With Two Vaccine Candidates
This article was originally published in PharmAsia News
Executive Summary
India's Bharat Biotech says it is working on two vaccines to tackle the rapidly spreading Zika virus, one of which is ready for preclinical trials.
You may also be interested in...
Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials
Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.